Table 5. AEs during follow-up.
AEs | ALC (n=30) | Placebo (n=26) | |
---|---|---|---|
Any AE | 4 (13.3%) | 2 (7.7%) | |
Dizziness | 0 | 1 | |
Cardiac arrest | 1 | 0 | |
Pyelonephritis | 1 | 0 | |
Fatty liver | 1 | 0 | |
Aggravation headache | 1 | 0 | |
Dyspesia | 0 | 1 |
AE: adverse event, ALC: Acetyl-L-carnitine.
*Pearson correlation; 0.967 (p<0.001) between 1st and 2nd test.